The Longitudinal Effects of Fenfluramine-Phentermine Use

  title={The Longitudinal Effects of Fenfluramine-Phentermine Use},
  author={Richard Fleming and Larry B. Boyd},
  pages={353 - 359}
The use of previous anorectic medications and the combined use of the anorectic medications fenfluramine and phentermine (Fen-Phen) have been associated with varying degrees of valvular regurgitation and pulmonary hypertension. More recent reports have suggested a lower incidence of both than was previously reported. Comparisons of patients with similar body mass index (BMI) have been missing as well as information regarding chamber dimensions and pressures. Using transthoracic 2D, M-mode, and… Expand
Longitudinal Effects of Fenfluramine—Phentermine Use
C careful cardiovascular evaluation of patients using drugs that have an affinity for serotonin receptors (or increase serotonin bioavailability) may be necessary, and consideration should also be given to developing either specific serotonin receptor antagonists or to using antiplatelet agents, which may decrease platelet activation and consequently serotonin release. Expand
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals
Regurgitant valvulopathy was common in individuals exposed to fenfluramines, more frequent in females, and associated with duration of use in all valves assessed and the incidence of surgery appeared to be substantially increased compared with limited general population data. Expand
Safety of ephedra and related anorexic medications
The ramifications of using anorexic medications, including ephedra, in modern society's efforts to address weight-related health problems are looked at along with some of the potential and proven consequences of such treatment. Expand
The Effect of Ephedra and High Fat Dieting: A Cause for Concern!
The following case presentation shows how an individual with exertional dyspnea and concerned about her weight was affected by both the ingestion of a low-carbohydrate diet and ephedra. Expand
Drug management of obesity--efficacy versus safety.
  • A. Astrup
  • Medicine
  • The New England journal of medicine
  • 2010
The history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing toExpand
Interactions with Drugs and Dietary Supplements Used For Weight Loss
Although multiple anti-obesity agents have progressed through the development process, few drug products have made it through the approval process due to safety or lack of efficacy concerns, and overweight or obese patients may turn to less regulated dietary supplements as a means to assist in weight loss. Expand
Zayıflama Amacıyla Kullanılan Çok Etken Maddeli Bazı Preparatların Toksikolojik Açıdan Değerlendirilmesi: Fen-Phen ve Usnik Asit
Fen-Phen and usnic acid preparations and the possible toxicological outcomes in the usage of these two kinds of preparations are reviewed. Expand
Examination of Behavioral Determinants in the Association between Depression and Obesity: The CARDIA study
Background: Obesity and depressive symptoms are major public health problems, as, epidemiological studies suggest that depressive symptoms are linked to obesity. However, potential behavioralExpand
Work-Related Outcomes of the Work-Family Interface: Why Organizations Should Care
Publisher Summary The objective of this chapter is to review the existing literature regarding outcomes associated with the work–family interface. First it reviews, work-related outcomes pertainingExpand
Performance of local authorities: Analysis on two different levels of quality adoption
This paper presents the findings of a study comparing the performance of local authorities with two different levels of adoption of quality management (QM). Data for this study were collected fromExpand


Valvular heart disease associated with fenfluramine-phentermine.
Concerns are raised that fenfluramine-phentermine therapy may be associated with valvular heart disease, which is arouse concern about serious potential adverse effects, including pulmonary hypertension and valvULAR heart disease. Expand
Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
Phen-fen therapy is associated with a low prevalence of significant valvular regurgitation, comparable to the normal offspring in the Framingham Heart Study, who are similar in age, gender, and geographical location. Expand
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
The use of fenfluramine or dexfen fluramine, particularly for four months or longer, is associated with an increased risk of newly diagnosed cardiac-valve disorders, particularly aortic regurgitation. Expand
Defining and Treating Heart Failure
Successful distinction between systolic and diastolic dysfunction requires the use of noninvasive tests such as echocardiography and radionuclide ventriculograms as discussed in Chapter 31, and invasive testing such as Ventriculography performed during cardiac catheterization. Expand
Density of muscularized arteries in the lung: Its role in congenital heart disease and its clinical significance.
The results indicate that congenital underdevelopment of the pulmonary arterial tree is uncommon and certainly not the rule in cases of congenital cardiac defects. Expand
Wagenvoort CA: Density of muscularized arteries in the lung: Its role in congenital heart disease and its clinical significance
  • Arch Pathol Lab Med
  • 1983
Weitgenhend reversibele primar vaskulare pulmonale hypertonie bei einem patienten mit menocil-einnahme
  • Z Kreislaufforsch 59:902-908,
  • 1970